Onto Innovation, Nano Dimension, NVE, and Clene have emerged as the nanotechnology stocks drawing the highest dollar trading volumes in recent days, according to MarketBeat's stock screener. Nanotechnology stocks represent shares in publicly traded companies whose primary business centers on developing, manufacturing, or commercializing technologies, materials, devices, or processes that operate at the nanoscale—roughly one to one hundred nanometers. These equities are typically classified as higher-risk, potentially high-reward growth investments due to extended research and development cycles and uncertain paths to commercial adoption.
Onto Innovation Inc. designs, develops, manufactures, and supports process control tools for optical metrology. The company produces lithography systems and process control analytical software alongside process and yield management solutions. Its product portfolio includes device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and measurements of transparent and opaque thin films.
Nano Dimension Ltd., operating in Israel and internationally, offers additive manufacturing solutions including 3D printers and micro manufacturing systems. The company's AME systems function as inkjet printers that deposit proprietary conductive and dielectric substances and integrate capacitors, antennas, coils, transformers, and electromechanical components. Its digital light processing printers produce production-grade polymer and composite parts, while industrial systems use a patented foil technology to fabricate ceramic and metal components.
NVE Corporation develops and sells spintronic devices—a nanotechnology relying on electron spin to acquire, store, and transmit information. The company manufactures spintronic products, primarily sensors and couplers designed for data acquisition and transmission across domestic and international markets.
Clene Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing clean-surfaced nanotechnology therapeutics. The company's lead candidate, CNM-Au8, has completed multiple Phase 2 clinical trials evaluating its safety and efficacy in patients with amyotrophic lateral sclerosis, early symptomatic ALS, chronic optic neuropathy, relapsing multiple sclerosis, and Parkinson's disease. Additional trials have examined the drug's effects on brain energy metabolites.
